Gene therapy for adenosine deaminase deficiency

Alessandro Aiuti, Francesca Ficara, Federica Cattaneo, Claudio Bordignon, Maria Grazia Roncarolo

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose of review: Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency has moved from the early trials of safety and feasibility to recent studies demonstrating efficacy and clinical benefit. This review describes the latest advances in gene therapy trials for this condition using peripheral blood lymphocytes or hematopoietic progenitors. Recent findings: In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA). A recent report showed that discontinuation of PEG-ADA resulted in a strong selective advantage of gene corrected T cells associated with restoration of T cell functions and antibody responses to neoantigen, but incomplete correction of the metabolic defect. Follow-up sgenetudies in patients treated with engineered hematopoietic progenitors in the early trials revealed low marking levels of long-term living progenitors and limited clinical effect. Recently, an improved gene transfer protocol in bone marrow CD34+ cells combined with low-dose busulfan resulted in multilineage, stable engraftment of transduced progenitors at substantial levels, restoration of immune functions, correction of the adenosine deaminase metabolic defect, and proven clinical benefit, in the absence of PEG-ADA. Overall, no adverse effect or toxicity has been observed in patients treated with adenosine deaminase gene transfer in mature lymphocytes or hematopoietic progenitors. Summary: Gene transfer in hematopoietic stem cells combined with nonmyeloablative conditioning is efficacious and might be extended to the treatment of other inherited and acquired disorders of the hematopoietic system.

Original languageEnglish
Pages (from-to)461-466
Number of pages6
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume3
Issue number6
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Adenosine Deaminase
Genetic Therapy
Lymphocytes
T-Lymphocytes
Genes
Hematopoietic System
Busulfan
Therapeutic Uses
Hematopoietic Stem Cells
Bone Marrow Cells
Antibody Formation
Safety
Severe combined immunodeficiency due to adenosine deaminase deficiency
Therapeutics
pegademase bovine

Keywords

  • Clinical trial
  • Gene transfer in hematopoietic stem cells
  • Gene transfer in peripheral blood lymphocytes
  • Severe combined immunodeficiency

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Gene therapy for adenosine deaminase deficiency. / Aiuti, Alessandro; Ficara, Francesca; Cattaneo, Federica; Bordignon, Claudio; Roncarolo, Maria Grazia.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 3, No. 6, 12.2003, p. 461-466.

Research output: Contribution to journalArticle

Aiuti, Alessandro ; Ficara, Francesca ; Cattaneo, Federica ; Bordignon, Claudio ; Roncarolo, Maria Grazia. / Gene therapy for adenosine deaminase deficiency. In: Current Opinion in Allergy and Clinical Immunology. 2003 ; Vol. 3, No. 6. pp. 461-466.
@article{5637819ee2274edebee631cb6a348e10,
title = "Gene therapy for adenosine deaminase deficiency",
abstract = "Purpose of review: Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency has moved from the early trials of safety and feasibility to recent studies demonstrating efficacy and clinical benefit. This review describes the latest advances in gene therapy trials for this condition using peripheral blood lymphocytes or hematopoietic progenitors. Recent findings: In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA). A recent report showed that discontinuation of PEG-ADA resulted in a strong selective advantage of gene corrected T cells associated with restoration of T cell functions and antibody responses to neoantigen, but incomplete correction of the metabolic defect. Follow-up sgenetudies in patients treated with engineered hematopoietic progenitors in the early trials revealed low marking levels of long-term living progenitors and limited clinical effect. Recently, an improved gene transfer protocol in bone marrow CD34+ cells combined with low-dose busulfan resulted in multilineage, stable engraftment of transduced progenitors at substantial levels, restoration of immune functions, correction of the adenosine deaminase metabolic defect, and proven clinical benefit, in the absence of PEG-ADA. Overall, no adverse effect or toxicity has been observed in patients treated with adenosine deaminase gene transfer in mature lymphocytes or hematopoietic progenitors. Summary: Gene transfer in hematopoietic stem cells combined with nonmyeloablative conditioning is efficacious and might be extended to the treatment of other inherited and acquired disorders of the hematopoietic system.",
keywords = "Clinical trial, Gene transfer in hematopoietic stem cells, Gene transfer in peripheral blood lymphocytes, Severe combined immunodeficiency",
author = "Alessandro Aiuti and Francesca Ficara and Federica Cattaneo and Claudio Bordignon and Roncarolo, {Maria Grazia}",
year = "2003",
month = "12",
doi = "10.1097/00130832-200312000-00007",
language = "English",
volume = "3",
pages = "461--466",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Gene therapy for adenosine deaminase deficiency

AU - Aiuti, Alessandro

AU - Ficara, Francesca

AU - Cattaneo, Federica

AU - Bordignon, Claudio

AU - Roncarolo, Maria Grazia

PY - 2003/12

Y1 - 2003/12

N2 - Purpose of review: Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency has moved from the early trials of safety and feasibility to recent studies demonstrating efficacy and clinical benefit. This review describes the latest advances in gene therapy trials for this condition using peripheral blood lymphocytes or hematopoietic progenitors. Recent findings: In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA). A recent report showed that discontinuation of PEG-ADA resulted in a strong selective advantage of gene corrected T cells associated with restoration of T cell functions and antibody responses to neoantigen, but incomplete correction of the metabolic defect. Follow-up sgenetudies in patients treated with engineered hematopoietic progenitors in the early trials revealed low marking levels of long-term living progenitors and limited clinical effect. Recently, an improved gene transfer protocol in bone marrow CD34+ cells combined with low-dose busulfan resulted in multilineage, stable engraftment of transduced progenitors at substantial levels, restoration of immune functions, correction of the adenosine deaminase metabolic defect, and proven clinical benefit, in the absence of PEG-ADA. Overall, no adverse effect or toxicity has been observed in patients treated with adenosine deaminase gene transfer in mature lymphocytes or hematopoietic progenitors. Summary: Gene transfer in hematopoietic stem cells combined with nonmyeloablative conditioning is efficacious and might be extended to the treatment of other inherited and acquired disorders of the hematopoietic system.

AB - Purpose of review: Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency has moved from the early trials of safety and feasibility to recent studies demonstrating efficacy and clinical benefit. This review describes the latest advances in gene therapy trials for this condition using peripheral blood lymphocytes or hematopoietic progenitors. Recent findings: In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA). A recent report showed that discontinuation of PEG-ADA resulted in a strong selective advantage of gene corrected T cells associated with restoration of T cell functions and antibody responses to neoantigen, but incomplete correction of the metabolic defect. Follow-up sgenetudies in patients treated with engineered hematopoietic progenitors in the early trials revealed low marking levels of long-term living progenitors and limited clinical effect. Recently, an improved gene transfer protocol in bone marrow CD34+ cells combined with low-dose busulfan resulted in multilineage, stable engraftment of transduced progenitors at substantial levels, restoration of immune functions, correction of the adenosine deaminase metabolic defect, and proven clinical benefit, in the absence of PEG-ADA. Overall, no adverse effect or toxicity has been observed in patients treated with adenosine deaminase gene transfer in mature lymphocytes or hematopoietic progenitors. Summary: Gene transfer in hematopoietic stem cells combined with nonmyeloablative conditioning is efficacious and might be extended to the treatment of other inherited and acquired disorders of the hematopoietic system.

KW - Clinical trial

KW - Gene transfer in hematopoietic stem cells

KW - Gene transfer in peripheral blood lymphocytes

KW - Severe combined immunodeficiency

UR - http://www.scopus.com/inward/record.url?scp=2642567436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642567436&partnerID=8YFLogxK

U2 - 10.1097/00130832-200312000-00007

DO - 10.1097/00130832-200312000-00007

M3 - Article

VL - 3

SP - 461

EP - 466

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 6

ER -